Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Two years ago, as Iveric Bio went through late-stage studies of its main experimental drug, it began attracting interest from potential buyers. Five companies ended …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look